AZN:NYSE
AstraZeneca PLC (US)
158,55 USD
arrow_downward
−0,40%(−0,63) 1 D.
10-12, 14:46:34 GMT−4 · USD
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „AZN“ įžvalgos...
Atidaryti
159,44 USD
Aukšta
159,44 USD
Žema
157,60 USD
Rinkos kapitalizacija
245,22 mlrd.
Vid. kiekis
2,91 mln.
Apimtis
1,73 mln.
Dividendas
2,03 %
Ketvirčio dividendai
0,81 USD
Teisių į dividendus praradimo data
2026-08-06
P/E santykis
23,70
52 sav. aukšta
212,71 USD
52 sav. žema
80,48 USD
Pajamos iš vienos akcijos
6,69 USD
Beta
0,30
Neapmokėtos akcijos
1,55 mlrd.
Darbuotojų skaičius
96 tūkst.
Atidaryti
159,44 USD
Aukšta
159,44 USD
Žema
157,60 USD
Rinkos kapitalizacija
245,22 mlrd.
Vid. kiekis
2,91 mln.
Apimtis
1,73 mln.
Dividendas
2,03 %
Ketvirčio dividendai
0,81 USD
Teisių į dividendus praradimo data
2026-08-06
P/E santykis
23,70
52 sav. aukšta
212,71 USD
52 sav. žema
80,48 USD
Pajamos iš vienos akcijos
6,69 USD
Beta
0,30
Neapmokėtos akcijos
1,55 mlrd.
Darbuotojų skaičius
96 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Yahoo Finance
·
prieš 3 valandas
AstraZeneca's efzimfotase alfa adult data point to $4.4bn peak sales potential, says Citi
Benzinga
·
prieš 5 valandas
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal
Kalkine Media
·
prieš 8 valandas
Why Is AstraZeneca (LSE:AZN) Stock In Focus After Its Summit Therapeutics Deal This Week?
Traders Union
·
prieš 10 valandų
Why is AstraZeneca stock up today? Summit $2B funding and GBX12,030 resistance test
Profilis
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
Apie „AstraZeneca PLC (US)“
Generalinis direktoriusPascal Soriot
Darbuotojai96,1 tūkst.
Įkurta1999-04-06
Pagrindinė būstinėKembridžas, Keimbridžšyras, Jungtinė Karalystė
Sektorius-
Svetainėastrazeneca.com